This article compares two approaches side by side to clarify how they differ in principle and practice. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold.
Ablation vs Surgical resection: Key Differences
Ablation destroys a tumor in situ through a needle-like applicator, while surgical resection physically removes the tumor and a margin of surrounding tissue. Ablation is minimally invasive and may be considered when surgery carries higher risk or when preserving organ tissue is a priority, as judged by the clinical team. Resection remains a well-established option for many tumors and can provide a specimen for pathological margin assessment, which ablation does not. The decision between ablation and resection is individualized and made within a multidisciplinary setting rather than by any single rule.
How INVAMED Supports Both Approaches
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). For intravesical therapy, the HyperTiss Intracavitary Hypothermia Set is positioned for adjunctive use alongside intravesical chemotherapy in bladder cancer. INVAMED's ablation portfolio spans several radiofrequency platforms, including the Peta RFA System for soft-tissue, liver, and nerve applications and the multi-application ThermoEdge RFA Platform, as well as the Fusion Intraosseous RFA System for spinal tumors.
Key Considerations
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
- All INVAMED ablation devices are intended for use by trained clinicians under appropriate image guidance and in accordance with the IFU.
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
Frequently Asked Questions
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Whether intraosseous ablation is appropriate, and how it fits within a broader oncologic and pain-management plan, is determined by the clinician. Wavelength, fiber type, and power settings influence the balance between vaporization and coagulation, and are selected according to the instrument system and clinical goal. Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions. Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy.
Related on INVAMED
- Oncology Ablation — product category
- How long is recovery after tumor ablation?
- What are the side effects of microwave ablation?
- Cryoablation for Renal Tumors: Technology, Uses and Considerations
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.